June 14, 2024
The Third Circuit will hear three separate appeals challenging Medicare's drug price negotiations together, according to a new order consolidating cases brought by AstraZeneca, Bristol-Myers Squibb and Janssen Pharmaceuticals in New Jersey and Delaware federal courts.
March 01, 2024
A Delaware federal judge on Friday rejected AstraZeneca's challenge to the Medicare price negotiation program, upholding the Biden administration's argument that the talks are voluntary.
December 04, 2023
AstraZeneca has chided the federal government for seeking a quick win against the drugmaker's challenge to the Medicare drug price negotiation program in a recent brief, arguing that the Centers for Medicare and Medicaid Services mistakenly believes it has "absolute authority to unilaterally dictate prices."
November 09, 2023
Nine health care experts and the AARP in briefs filed Thursday asked a Delaware federal court to reject AstraZeneca's challenge to the Inflation Reduction Act's provision allowing the government to negotiate drug prices with pharmaceutical companies.
November 02, 2023
The federal government has urged a Delaware federal judge not to block the Inflation Reduction Act's provision allowing it to negotiate drug prices with pharmaceutical companies, arguing that AstraZeneca doesn't have standing to bring its claims, which, in any event, are meritless.
October 06, 2023
Lawsuits from Big Pharma and big business challenging Medicare's new power to negotiate drug prices are hurtling toward pivotal tests of lofty legal theories and the Biden administration's creative efforts to save its signature health care accomplishment. Here, Law360 explores the litigation landscape in a detailed map that will be updated as the saga evolves.
September 27, 2023
Pharmaceutical company AstraZeneca asked a Delaware federal judge Tuesday to rule that the Inflation Reduction Act's provision allowing the government to negotiate drug prices oversteps statutory authority and is ultimately unlawful.
September 01, 2023
Novartis Pharmaceuticals Corp. on Friday joined the growing list of pharmaceutical companies challenging the Inflation Reduction Act, filing suit in New Jersey federal court just days after the Biden administration revealed the list of drugs in the inaugural round of Medicare price negotiations.
August 25, 2023
AstraZeneca joined a chorus of pharmaceutical companies and other parties in challenging the Inflation Reduction Act's provision allowing Medicare to negotiate drug prices with drugmakers.